In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Enhanched external counterpulsation therapy improves clinical outcomes, quality of life and functional effort capacity in patients with symptomatic heart failure

Session Poster session 1 Saturday 08:30 -17:30

Speaker

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P261

Authors : M Refiker Ege (Ankara,TR), MB Yilmaz (Sivas,TR), O Soran (Pittsburgh,US)

15 views

Authors:
M Refiker Ege1 , MB Yilmaz2 , O Soran3 , 1Ankara Koru Hospital, cardiology department - Ankara - Turkey , 2Cumhuriyet University - Sivas - Turkey , 3University of Pittsburgh - Pittsburgh - United States of America ,

Citation:
European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 55

Objectives:Chronic heart failure is an important health problem that limits the daily life,quality of life,effort capacity and physiological condition of the patients. In subset of these patients symptoms persist despite optimal medical management. Enhanced External Counterpulsation (EECP) is a non-invasive Food and Drug Administration approved therapy which improves symptoms and clinical outcomes in patients with heart failure. However, there is limited data in Turkish cohort. In this study, we investigated the clinical effects of EECP on multiple paramaters associated with quality of life, funcional effort capacity and physiological status in Turkish patients with symptomatic chronic heart failure.

Methods: 21 individuals who were diagnosed with symptomatic chronic heart failure (left ventricular ejection fraction ≤40 %) with NYHA II-III were enrolled in the study. Eligible patients were assigned to 35 -session EECP treatment. NYHA classification, SF 36 quality of life quastionaire, Minnesota living heart failure quastionaire, quality of life index cardiac version IV and Beck depression scale were assessed and 6 minute walk test was performed before and after EECP treatment.

Results: The mean age of the patients was 57.4 ± 12.5 years. Patients underwent an EECP treatment course of 35 hours with an exellent compliance rate. EECP therapy resulted in significant improvement in NYHA functional class, quality of life index, effort capacity and pyhsiological condition in all patients without any adverse event (p = 0,001) (Table 1).

Conclusion: EECP treatment significantly improved clinical parameters and effort capacity in patients with symptomatic heart failure. These results suggest that EECP is an effective and a safe therapy in Class II-III heart failure patients whose symptoms persist despite optimal medical management.

Before EECP

After EECP

N

P

NYHA class

1.6±1.5

0.6±0.7

21

0.001

SF36 score

75.5±5.2

119.9±13.6

21

0.001

Minnesota living heart failure score

66.7±29.5

22.8±26.2

21

0.001

BECK score

8.2±7.9

2.4±4.6

21

0.001

Quality of life index cardiac version-IV

288.8±34.1

346.3±49.5

21

0.001

6 minute walk test

237±46.8

364±50.9

21

0.001

The effects of EECP on multiple parameters


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are